Ellagic acid exerts anti-fibrotic effects on hypertrophic scar fibroblasts via inhibition of TGF-β1/Smad2/3 pathway

Xianjun Liu1,2†, Xinxin Gao3,4†, Hao Li1,2, Zhandong Li1,2, Xiaoe Wang1, Li Zhang1, Bo Wang3, Xinxin Chen3,4, Xianglong Meng3,4* and Jiaao Yu3,4*

Abstract
Hypertrophic scar (HS) is a kind of serious pathological scar with no currently effective treatment. HS fibroblasts (HSFs) are the main effector cells for HS formation. Ellagic acid (EA) exerts regulatory effects in some diseases, but its role in HS remains unclear. This study aimed to evaluate the effect of EA on the fibrotic phenotypes of HSFs and to further investigate the downstream signaling mechanism. The cell counting kit-8 (CCK-8) assay was used to perform cytotoxicity and proliferation assays. HSFs migration was assessed using wound healing and transwell assays. HSFs contraction was measured by a collagen lattice contraction assay and detection of α-smooth muscle actin (α-SMA) expression. The levels of mRNA and protein were determined by qPCR and western blotting, respectively. The results showed that EA inhibited the proliferation, migration, and contraction of HSFs and collagen expression in HSFs in a dose-dependent manner. Furthermore, EA not only suppressed the Smad2/3 pathway but also reversed TGF-β1-induced activation of the Smad2/3 pathway and up-regulation of the fibrotic cellular phenotypes in HSFs. These findings demonstrate that EA exerts anti-fibrotic effects on HSFs by blocking the TGF-β1/Smad2/3 pathway, which indicates that EA is a potential therapeutic candidate for treatment of HS.

Keywords: Collagen, Contraction, Ellagic acid, Hypertrophic scar fibroblasts, Migration, Proliferation, Smad pathway, TGF-β1

Introduction
Hypertrophic scar (HS) is a severe skin fibrotic disease that often occurs after burn injury. HS is generally raised, red, itchy, or painful, and can even lead to movement dysfunction. These adverse symptoms result in not only physical but also psychological injury to the patients [1]. Statistics show that up to 70% of burn patients suffer from HS [2]. In recent years, a few treatments have been developed; however, there is currently no effective therapy for HS. Previous studies have demonstrated that the pathological mechanism of HS formation is mainly identified by aberrant deposition of extracellular matrix (ECM), especially collagen I and III, and overactive hypertrophic scar fibroblasts (HSFs) are the effector cells contributing to the progression of HS [3]. It is meaningful to explore an approach that could effectively attenuate the fibrotic cellular phenotypes of HSFs, including proliferation, migration, contraction, and collagen expression.

Ellagic acid (EA) (molecular formula C14H6O8, Fig. 1A) is a natural plant polyphenolic compound that is abundant in various fruits and nuts. Previous studies have mostly focused on the antioxidant, antihepatotoxic, and antitumor effects of EA [4–6]. Additionally, a few studies have indicated that EA exerts anti-fibrotic effects in liver, pancreatic, and cardiac fibrosis [7–9]. However, the effect of EA on HS formation remains unclear.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

*Correspondence: mengxljdyy@jlu.edu.cn; yuja@jlu.edu.cn
†Xianjun Liu and Xinxin Gao contributed equally to this work
3 Department of Burns Surgery, The First Hospital of Jilin University, No. 1409 Ximinzhu Street, Changchun 130000, China
Full list of author information is available at the end of the article
The Smad2/3 signaling pathway is a canonical fibrosis-associated signal transduction pathway, activation of which regulates a spectrum of pathological cellular behaviors of HSFs [3]. TGF-β1, a well-known pro-fibrotic growth factor, is a significant upstream stimulator of the Smad2/3 pathway. Previous studies have found that TGF-β1 promotes the proliferation, migration, and contraction of HSFs and collagen synthesis in HSFs by activating the Smad2/3 pathway [10]. Proper regulation of the TGF-β1/Smad2/3 pathway in HSFs is considered a promising strategy for hindering HS formation.

In this study, we evaluated the effects of EA on the proliferation, migration, and contraction of HSFs and collagen expression in HSFs. Importantly, we further investigated the association between the TGF-β1/Smad2/3 pathway and EA-induced regulation of HSFs.

**Materials and methods**

**Antibodies and drugs**

The primary antibodies used for western blotting in this study were as follows: anti-α-smooth muscle actin (α-SMA) (1:1000; cat. no. ab32575; Abcam, Cambridge, UK), anti-collagen I (1:1000; cat. no. AF7001; Affinity, OH, USA), anti-collagen III (1:1000; cat. no. AF0136; Affinity), anti-Smad2 (1:5000; cat. no. ab40855; Abcam), anti-Smad2 (phospho S255) (1:5000; cat. no. ab188334; Abcam), anti-Smad3 (1:5000; cat. no. ab40854; Abcam), anti-Smad3 (phospho S423 + S425) (1:2000; cat. no. ab52903; Abcam), and anti-GAPDH (1:5000; cat. no. 10494-1-AP; Proteintech, IL, USA). Secondary antibodies (1:5000; goat anti-mouse cat. no. SA00001-1; goat anti-rabbit cat. no. SA00001-2; Proteintech) were used for western blotting. EA (cat. no. B21073; Yuanye Biotech, Shanghai, China) was dissolved in 1 M NaOH. The final concentration of NaOH was ≤ 0.1% (v/v) and did not contribute to toxicity. TGF-β1 (cat. no. bs-2266P; Bioss, Beijing, China) was diluted with sterile double-distilled water.

**Cells isolation and culture**

Normal human dermal fibroblasts (HDFs) (cat. no. #2320) were purchased from Sciencell, and three cell lines were obtained for subsequent cytotoxicity assay by parallel culture. HSFs were primarily cultured from the scar tissues of five patients (3 men and 2 women; aged 10–50 years) who suffered HS and had a cicatrectomy in the Department of Burns Surgery of the First Hospital of Jilin University between January and April 2018.
Protocols were approved by the Ethics Committee of the First Hospital of Jilin University (no. 2017-088) and were conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all donors before surgery. Briefly, the epidermis and subcutaneous adipose tissue of HS tissues were shaped. Next, the tissues were cut into approximately 1 mm³ sections under sterile conditions. After washing, sections were placed in a cell culture dish and incubated in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and double antibiotics (penicillin, 100 U/mL; streptomycin, 0.1 mg/mL) at 37 °C with 5% CO₂. All cell culture reagents were supplied by Gibco (Thermo Fisher Scientific, MA, USA). When fibroblasts reached approximately 90% confluence, they were trypsinized and passaged. Cells from passages 2–4 were used in the subsequent experiments.

Cytotoxicity and proliferation assays
A cell counting kit 8 (CCK-8) assay was used for cytotoxicity and proliferation assays. Viable HDFs or HSFs counts were indirectly detected by measuring the optical density (OD) values. Cytotoxicity assay was performed as described below. Briefly, HDFs were seeded at 2 × 10⁴ cells per well in a 96-well culture plate, with three replicates per sample, excluding the use of external rows and columns, to avoid edge effects. After complete cell attachment, HDFs or HSFs were processed according to the experimental requirements. After treatment for 48 h, 10 μL of CCK-8 (APExBIO, Houston, USA) solution was added to each well. After incubation for 2 h at 37 °C, the absorbance was measured at 450 nm wavelength using a microplate reader (Thermo Fisher Scientific, MA, USA). The cytotoxicity assay results were expressed as cell survival rates. Cell survival rate (%) = (OD value of treated group – OD value of blank) / (OD value of control group - OD value of blank) × 100. As for the proliferation assay, HSFs were seeded at 5 × 10⁵ cells per well in a 96-well culture plate, and the OD values were tested at time points 0, 24, 48, and 72 h after treatment. In addition to these, the method of OD value detection was the same as the cytotoxicity assay. The proliferation assay results were expressed as OD values.

Wound healing assay
A wound healing assay was used to assess the migration of HSFs. In brief, HSFs were cultured in a 6-well culture plate at a density of 1 × 10⁵ cells/cm² with DMEM containing 10% FBS until the cell confluence reached 100%. A scratch wound was made in the middle of each well using a 1-ml pipette tip. After washing with PBS, the culture medium was changed to serum-free DMEM, with EA or TGF-β1 according to experimental requirements. At the time points 0, 24, and 48 h after scratching, images were acquired at three random fields of view using an inverted microscope (magnification 40 ×; Olympus Corporation, Tokyo, Japan). Wound area was measured using ImageJ software (version 1.51w). Migration ability of HSFs was evaluated using the data shown as migration rate (%) = (initial wound area – wound area at 24 or 48 h) / initial wound area × 100.

Transwell assay
A transwell assay was used to assess the migration of HSFs. Briefly, 2 × 10⁵ HSFs were seeded in the upper chambers of transwell plates (6-well, 8 μm; Millicell, MA, USA) incubated in serum-free DMEM, and the lower chambers were supplied with DMEM containing 10% FBS, with EA or TGF-β1 according to experimental requirements. After 24 h, non-migrated HSFs on the upper face of the polycarbonate membrane were removed with a cotton swab, and migrated HSFs were fixed with methanol and stained with Giemsa dye solution (cat. no. R20649; Yuanye Biotech, Shanghai, China). Images of each well were captured at three random fields of view using an OLYMPUS inverted microscope. The cells were counted using ImageJ software.

Collagen lattice contraction assay
A collagen lattice contraction assay was used to assess the contraction ability of HSFs. HSFs were mixed with rat tail tendon collagen (cat. no. C8062; Solarbio, Beijing, China). The final collagen concentration of the mixture was 1 mg/mL, with a cell density of 2.5 × 10⁵ cells/mL. The mixture was added to a 24-well cell culture plate (200 μL/well) and incubated at 37 °C for 1 h. After coagulation, 500 μL serum-free DMEM, with EA or TGF-β1 according to experimental requirements, was added onto the gel. A picture of each sample was captured at 48 h. The area of the gels calculated using ImageJ software. The contraction rate was presented as a measure of HSFs contraction: contraction rate (%) = (well area – gel area)/well area × 100.

Real-time quantitative PCR (qPCR)
RNA was isolated, and qPCR was carried out. Briefly, total RNA was isolated from the samples using TRIzol® reagent (Invitrogen, USA). cDNA was synthesized using the TransScript All-in-One First-Strand cDNA Synthesis SuperMix (TransGen Biotech, Beijing, China). FastStart Universal SYBR Green Master (ROX) (Roche Diagnostics, Mannheim, Germany) was used for qPCR with a Stratagene Mx3005P instrument (Agilent Technologies, USA). The reaction conditions were as follows: initial denaturation at 95 °C for 10 min; 40
cycles of denaturation at 95 °C for 30 s and annealing at 60 °C for 1 min; dissociation at 95 °C for 1 min, annealing at 55 °C for 30 s, and final extension at 95 °C for 30 s. The primers used in qPCR are listed in Table 1. The expression levels of target genes were normalized to that of GAPDH, and the $2^{-\Delta\Delta C_t}$ method was used to calculate the relative mRNA levels [11]. Each sample was run in triplicate.

Western blotting
Harvested fibroblasts were processed with RIPA lysis buffer (CST, USA) supplemented with phenylmethylsulphonyl fluoride (Thermo Fisher Scientific, MA, USA), protease inhibitor cocktail (TransGen Biotech, Beijing, China), and phosphatase inhibitor cocktail (TransGen Biotech). Protein concentration was measured using a bicinchoninic acid (BCA) protein assay kit (Beyotime Institute of Biotechnology, Nantong, China). Samples were separated using SDS-PAGE gels, and subsequently electro-transferred to PVDF membranes (Millipore, MA, USA) for immunoblotting analysis. After blocking with 5% bovine serum albumin (Sigma-Aldrich, MO, USA) in TBST (0.5% Tween-20) for 1 h at room temperature, the PVDF membranes were incubated with primary antibodies at 4 °C overnight. Following incubation with the appropriate horse-radish peroxidase-conjugated secondary antibodies for 1 h at room temperature, proteins were detected with the EasySee western blotting kit (TransGen Biotech) using a myECL™ imager (Thermo Fisher Scientific), and the band intensities were quantified by calculation of gray values using ImageJ software. Data were collected from three independent experiments.

Statistical analysis
The quantified data are presented as the mean ± standard deviation (SD). The differences between the two groups were analyzed by Student’s t-test using the GraphPad Prism (version 7.00) statistical package. A value of P<0.05 indicated a statistically significant difference.

Results and discussion
EA inhibited HSFs proliferation in a dose-dependent manner
First, we performed cytotoxicity assay for EA to HDFs by a CCK-8 assay. As shown in Fig. 1B, there was no significant difference in cell survival rate between each EA-treated group (concentration ≤ 150 μM) and the control group. This result suggested a concentration range, at which EA is harmless to normal HDFs. Then, to evaluate the effect of EA on HSFs proliferation, a CCK-8 assay was performed. As shown in Fig. 1C and D, HSFs proliferation in the EA-treated groups was attenuated as compared with that of the control group. There was no significant difference in cell viability between the 10 μM group and the control group at 24 and 48 h. The data demonstrated a significant decrease in HSFs proliferation in the 10 μM group as compared with that of the control group at 72 h; HSFs proliferation in the 50 and 100 μM groups was significantly lower than that of the control group at all time points. Additionally, HSFs proliferation in the 50 and 100 μM groups was significantly lower than that of the 10 μM group at all time points. HSFs proliferation in the 100 μM group was significantly lower than that of the 50 μM group at all time points except for 24 h. All these data indicate that EA inhibited HSFs proliferation in a dose-dependent manner.

EA inhibited HSFs migration in a dose-dependent manner
The effect of EA on HSFs migration was assessed using wound healing and transwell assays. As shown in Fig. 2A and 2B, at 24 and 48 h after scratching, the migration rate of HSFs significantly decreased with increasing EA dose. In addition, the results of the transwell assay (Fig. 2C and 2D) showed that the migrated HSFs were significantly reduced with increasing EA dose, consistent with the results of wound healing assay. These data demonstrate that EA inhibited HSFs migration in a dose-dependent manner.

EA inhibited HSFs contraction in a dose-dependent manner
To evaluate the effect of EA on HSFs contraction, a collagen lattice contraction assay was performed, and the expression of α-SMA, which is correlated with the contractive ability of HSFs, was detected using qPCR and western blotting. As shown in Fig. 3A and B, with increasing EA dose, the contraction rate significantly decreased. As for the detection of α-SMA, encoded by ACTA2 gene, the data of qPCR showed that the mRNA level of ACTA2

| Table 1 | Sequences of primers for qPCR |
|---------|-------------------------------|
| **Forward (5’→3’)** | **Reverse (5’→3’)** |
| ACTA2 | GACAAAGGCTCTGGGCTCCTGAAGAA | TGTCACTTCAGCAGATGTCG |
| COL1A1 | ACCACGTCTCCATGTGGCAAGA | CCGTACCTCAAGATGTCG |
| COL1A2 | GAGGGCGAACGAGCCGCAGC | CTGCACCTCAAGATGTCG |
| COL3A1 | CACACGGGAAACACTGGGAC | GCCAGCAGCAGATCAGCAG |
| GAPDH | GCCACGGCTCAAGCCTGAGAAC | TGGTGAAGACGCCGAGTGA |

EA inhibited HSFs proliferation in a dose-dependent manner
First, we performed cytotoxicity assay for EA to HDFs by a CCK-8 assay. As shown in Fig. 1B, there was no significant difference in cell survival rate between each EA-treated group (concentration ≤ 150 μM) and the control group. This result suggested a concentration range, at which EA is harmless to normal HDFs. Then, to evaluate the effect of EA on HSFs proliferation, a CCK-8 assay was performed. As shown in Fig. 1C and D, HSFs proliferation in the EA-treated groups was attenuated as compared with that of the control group. There was no significant difference in cell viability between the 10 μM group and the control group at 24 and 48 h. The data demonstrated a significant decrease in HSFs proliferation in the 10 μM group as compared with that of the control group at 72 h; HSFs proliferation in the 50 and 100 μM groups was significantly lower than that of the control group at all time points. Additionally, HSFs proliferation in the 50 and 100 μM groups was significantly lower than that of the 10 μM group at all time points. HSFs proliferation in the 100 μM group was significantly lower than that of the 50 μM group at all time points except for 24 h. All these data indicate that EA inhibited HSFs proliferation in a dose-dependent manner.

EA inhibited HSFs migration in a dose-dependent manner
The effect of EA on HSFs migration was assessed using wound healing and transwell assays. As shown in Fig. 2A and 2B, at 24 and 48 h after scratching, the migration rate of HSFs significantly decreased with increasing EA dose. In addition, the results of the transwell assay (Fig. 2C and 2D) showed that the migrated HSFs were significantly reduced with increasing EA dose, consistent with the results of wound healing assay. These data demonstrate that EA inhibited HSFs migration in a dose-dependent manner.

EA inhibited HSFs contraction in a dose-dependent manner
To evaluate the effect of EA on HSFs contraction, a collagen lattice contraction assay was performed, and the expression of α-SMA, which is correlated with the contractive ability of HSFs, was detected using qPCR and western blotting. As shown in Fig. 3A and B, with increasing EA dose, the contraction rate significantly decreased. As for the detection of α-SMA, encoded by ACTA2 gene, the data of qPCR showed that the mRNA level of ACTA2
decreased with an increase in EA dose (Fig. 3C). Western blotting showed that the change in α-SMA protein level was in line with that of its mRNA level. All these measures indicated that EA inhibited HSFs contraction in a dose-dependent manner.

**EA inhibited the expression of collagen I and III in HSFs in a dose-dependent manner**

To evaluate the effect of EA on collagen synthesis in HSFs, qPCR and western blotting were used to detect the mRNA and protein levels of collagen I and III, respectively. As shown in Fig. 4A, the mRNA levels of COL1A1, COL1A2, and COL3A1 were significantly reduced with increasing EA dose, in addition to COL1A2 expression in the 10 μM group. The change in protein levels of collagen I and III was consistent with the change in mRNA levels (Fig. 4B). These results demonstrate that EA inhibited the expression of collagen I and III in HSFs in a dose-dependent manner.

**EA inhibited TGF-β1/Smad2/3 signaling pathway in HSFs**

Based on the above findings, we assessed the effect of EA on HS-associated signaling pathway in HSFs. The protein levels of total (t)-Smad2, p-Smad2, t-Smad3, and p-Smad3 were detected using western blotting, and the ratios of p-Smad2/t-Smad2 and p-Smad3/t-Smad3 were calculated to evaluate the Smad2/3 pathway. As shown in Fig. 5A and B, the ratios of p-Smad2/t-Smad2 and p-Smad3/t-Smad3 significantly decreased in the EA-treated group (100 μM), and significantly increased in the TGF-β1-treated group (10 ng/mL) as compared with those in the control group. Furthermore, EA treatment significantly reversed TGF-β1-induced up-regulated phosphorylation of Smad2 and 3. These data indicated that EA inhibited the TGF-β1/Smad2/3 signaling pathway in HSFs.
EA inhibited TGF-β1-induced up-regulation of HSFs proliferation, migration, and contraction, and collagen synthesis in HSFs

To further investigate the association between EA-induced inhibition of fibrotic phenotypes and TGF-β1/Smad2/3 signaling pathway in HSFs, we measured the effect of EA (100 μM) on TGF-β1-induced up-regulation of HSFs proliferation, migration, and contraction, and collagen synthesis in HSFs. The results showed that EA significantly reversed TGF-β1-induced up-regulation of proliferation as assessed by CCK-8 assay (Fig. 6A), migration as assessed by wound healing assay (Fig. 6B) and transwell assay (Fig. 6C), contraction as assessed by collagen lattice contraction assay (Fig. 6D) and α-SMA detection (Fig. 6E and F), and collagen synthesis as assessed by collagen I and III detection (Fig. 6E and F). These results demonstrate that EA exerted inhibitory effects on TGF-β1-induced fibrotic phenotypes of HSFs.

Discussion

HS, which often occurs after burn injury, is gradually becoming a challenge for clinical workers [1]. Although a few therapies, such as laser therapy, compression garments, and topical drug application, have
been developed, there is not yet a satisfactory treatment for HS [12]. In recent years, pre-clinical studies have indicated that some natural plant extracts exhibit anti-fibrotic properties in vitro and/or in vivo [13–15]. Natural extracts are often well-tolerated. Our work, for the first time, has demonstrated that EA attenuated multiple fibrotic phenotypes of HSFs in vitro.

The over-proliferation of HSFs is considered to be associated with HS formation. In studies on the role of EA in fibrotic diseases, to date, EA was reported to exert a hindering effect on the growth of rat PDGF-treated pancreatic stellate cells [16] and rat cardiac fibroblasts [9]. Similarly, our work showed that EA significantly inhibited HSFs proliferation (Fig. 1). Moreover, various studies focusing on the role of EA in multiple cancer types have also reported its inhibitory effect on cell proliferation[6].

Studies on enhanced migration, a pathological cellular behavior of HSFs, are gradually increasing. In addition to the inhibitory action of EA on the migration of a few cancer cell lines [6], Masamune et al. found that EA attenuated PDGF-induced migration of pancreatic stellate cells [16], and Lin et al. found similar inhibitory effect of EA on rat cardiac fibroblasts [9]. Consistent with these studies, our work found that EA suppressed HSFs migration (Fig. 2).

The contraction of human dermal fibroblasts plays an important role in wound healing, but excessive contraction of HSFs contributes significantly to the inelasticity and contracture of HS[17]. Some previous studies have reported that EA could reduce the ventricular myocytes of mice and rats in vitro [18, 19]. Similarly, our results indicated that EA inhibited HSFs contraction (Fig. 3).

These findings illustrate the similar effect of EA on the same phenotypes of different diseases cells.

Collagen, particularly collagen I and III, the most abundant components of ECM deposition in HS, is considered to be associated with the specific manifestations of HS that is hard and raised above the skin [20]. A previous study by Reanmongkol et al. found that EA has a role in wound healing by a rat dermal wound model, while it is not effective on collagen accumulation [21]. In our study, EA reduced the expression of collagen I and III in HSFs (Fig. 4), similar to a recent study conducted by Lin et al. which demonstrated that EA inhibited the expression of collagen I and III in rat cardiac fibroblasts[9]. This indicates that EA possesses therapeutic potential against fibrosis, which makes it worthy of further research.

The Smad2/3 pathway is widely recognized as a major signaling pathway that leads to HS formation [3, 22]. Activation of the Smad2/3 pathway causes multiple fibrotic phenotypes of HSFs. TGF-β1 induces the phosphorylation of Smad2 and 3 by binding to cell surface TGF-β receptors. Phosphorylated Smad2 and 3 translocate to the nucleus with cooperation of Smad4, and these molecules, in the form of a transcriptional complex, regulate downstream target genes expression [23]. Many studies have validated that blocking the TGF-β1/Smad2/3 pathway can effectively suppress the pathological phenotypes of HSFs [24]. Our study demonstrated that EA suppressed HSFs proliferation, migration, and contraction, and expression of collagen I and III in HSFs by inhibiting the TGF-β1/Smad2/3 signaling pathway (Fig. 7, created with BioRender.com). However, the upstream mechanism driving EA-induced inhibition of this pathway still
needs further investigation. In addition to mechanism study, further in vivo experiment is needed. A rabbit ear scar model should be a good candidate, which is widely used in the studies on HS [25].

In conclusion, this study demonstrates that EA exerts inhibitory effects on HSFs proliferation, migration, and contraction, and collagen synthesis in HSFs by inhibiting the TGF-β1/Smad2/3 signaling pathway. These findings present EA as a promising novel drug candidate for treatment of HS, and provide theoretical support for further in vivo experiments and clinical application in the future. Moreover, this research extends our understanding of the biological activity of EA.
Acknowledgements
This study was supported by the PhD Research Project of Jilin Engineering Normal University (no. BSKJ201923), the Fund Project of the Finance Department of Jilin Province (no. JLWSRCZX2020-002), the Fund Project of the Development and Reform Commission of Jilin Province (no. 2020CD49), the Fund Project of Jilin Provincial Science and Technology Department (no. 20200404166YY), and the grants from the First Hospital of Jilin University (no. JDYGH2019006 and no. BQEGCZX2019004).

We thank Bethune Institute of Epigenetic Medicine of the First Hospital of Jilin University for providing experimental conditions for part of cell experiments in this study.

Authors’ contributions
JY and XM designed the concept of the study, reviewed and revised the manuscript. XL and XG wrote the original draft and performed the most experimental tasks. XM, HL, ZL, XW, LZ, BW, and XC performed partial experiments and experimental validation. XM, XL, and XG contributed to results analysis. JY and XL contributed to funding acquisition. All the authors read and approved the final vision of the manuscript.

Declarations
Competing interest
The authors declare that they have no conflict of interest.

Author details
1 College of Food Engineering, Jilin Engineering Normal University, No. 3050 Kaixuan Street, Changchun 130000, China. 2 Measurement Biotechnology Research Center, Jilin Engineering Normal University, No. 3050 Kaixuan Street, Changchun 130000, China. 3 Department of Burns Surgery, The First Hospital of Jilin University, No. 1409 Ximinzh Street, Changchun 130000, China. 4 Jilin Provincial Skin Repair and Regeneration Engineering Research Center, the First Hospital of Jilin University, No. 1409 Ximinzh Street, Changchun 130000, China. 5 Institute for Interdisciplinary Biomass Functional Materials Studies, Jilin Engineering Normal University, No. 3050 Kaixuan Street, Changchun 130000, China.

Received: 23 June 2021 Accepted: 31 August 2021 Published online: 15 September 2021

References
1. Finnerty C, Jeschke M, Branski L, Barret J, Dziewulski P, Herndon D (2016) Hypertrophic scarring: the greatest unmet challenge after burn injury. Lancet (London, England) 388(10052):1427–1436
2. Bombaro K, Engrav L, Carrougher G, Wiechman S, Faucher L, Costa B et al (2003) What is the prevalence of hypertrophic scarring following burns? Burns J Int Soc Burn Inj 29(4):299–302
3. Amini-Nik S, Yousef Y, Jeschke M (2018) Scar management in burn injuries using drug delivery and molecular signaling: current treatments and future directions. Adv Drug Deliv Rev 123:135–154
4. Rios J, Giner R, Marín M, Recio M (2018) A pharmacological update of ellagic acid. Planta Med 84(15):1068–1093
5. García-Niño W, Zazueta C (2015) Ellagic acid: pharmacological activities and molecular mechanisms involved in liver protection. Pharmacol Res 97:84–103
6. Ceci C, Lical P, Tentori L, De Martino M, Miano R, Graziani G (2018) Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid. Nutrients 10(11):1756
7. Devipriya N, Sudheer A, Sriivasan M, Menon V (2007) Effect of ellagic acid, a plant polyphenol, on fibrotic markers (MMPs and TIMPs) during alcohol-induced hepatotoxicity. Toxicol Mech Methods 176(6):349–356
8. Suzuki N, Masamune A, Kikuta K, Watanabe T, Satoh K, Shimosegawa T (2009) Ellagic acid inhibits pancreatic fibrosis in male Wistar Bonn/Kobori rats. Dig Dis Sci 54(4):802–810
9. Lin C, Wei D, Xin D, Pan J, Huang M (2019) Ellagic acid inhibits proliferation and migration of cardiac fibroblasts by down-regulating expression of HDAC1. J Toxicol Sci 44(6):425–433
10. Lian N, Li T (2016) Growth factor pathways in hypertrophic scars: Molecular pathogenesis and therapeutic implications. Biomed Pharmacother 84:42–50

11. Livak K, Schmittgen T (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif) 25(4):402–408

12. Zhang J, Li Y, Bai X, Li Y, Shi J, Hu D (2018) Recent advances in hypertrophic scar. Histol Histopathol 33(1):27–39

13. Bahri S, Ben Ali R, Abidi A, Jameledine S (2017) The efficacy of plant extract and bioactive compounds approaches in the treatment of pulmonary fibrosis: A systematic review. Biomed Pharmacother Biomed Pharmacother 93:666–673

14. Chen D, Hu H, Wang Y, Feng Y, Cao G, Zhao Y (2018) Natural products for the prevention and treatment of kidney disease. Phytomed Int J Phytother Phytopharmacol 50:50–60

15. Domitrovic R, Potočnjak I (2016) A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives. Arch Toxicol 90(1):39–79

16. Masamune A, Satoh M, Kikuta K, Suzuki N, Satoh K, Shimosegawa T (2005) Ellagic acid blocks activation of pancreatic stellate cells. Biochem Pharmacol 70(6):869–878

17. Nedelec B, Ghalary A, Scott P, Tredget E (2000) Control of wound contraction. Basic Clin Features Hand Clin 16(2):289–302

18. Namekata I, Hamaguchi S, Wakasugi Y, Othara M, Hirota Y, Tanaka H (2013) Ellagic acid and gingerol, activators of the sarco-endoplasmic reticulum Ca2+-ATPase, ameliorate diabetes mellitus-induced diastolic dysfunction in isolated murine ventricular myocardia. Eur J Pharmacol 706:48–55

19. Olgar Y, Ozturk N, Usta C, Puddu P, Ozdemir S (2014) Ellagic acid reduces L-type Ca2+ current and contractility through modulation of NO-GC-cGMP pathways in rat ventricular myocytes. J Cardiovasc Pharmacol 64(6):567–573

20. Coentro J, Pugliese E, Hanley G, Raghunath M, Zeugolis D (2019) Current and upcoming therapies to modulate skin scarring and fibrosis. Adv Drug Deliv Rev 146:37–59

21. Mo J, Panichayupakaranant P, Kaewnopparat N, Nitiruangjaras A, Reanmongkol W (2014) Wound healing activities of standardized pomegranate rind extract and its major antioxidant ellagic acid in rat dermal wounds. J Nat Med 68(2):377–386

22. Shirakami E, Yamakawa S, Hayashida K (2020) Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence. Burns Trauma 8:tkz003

23. Hu H, Chen D, Wang Y, Feng Y, Cao G, Vaziri N et al (2018) New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact 292:76–83

24. Zhang T, Wang X, Wang Z, Lou D, Fang Q, Hu Y et al (2020) Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation. Biomed Pharmacother Biomed Pharmacother 129:110287

25. Demergue S, Jorgensen C, Noël D (2015) Advances in research in animal models of burn-related hypertrophic scarring. J Burn Care Res 36(5):e259–e266

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.